tRNAスレオニル化の破壊はRIG-Iを介した抗腫瘍免疫応答を誘発する
Cléa Dziagwa1, Christian Seca1, Coralie Capron2
1Laboratory of Cancer Signaling, GIGA-Institute, University of Liège, Liège, Belgium.
Nature communications
|February 24, 2026
まとめ
O-シアログリコプロテインエンドペプチダーゼ(OSGEP)は、mRNA翻訳を制御することにより、がんの免疫回避を調節する。OSGEPの喪失はメラノーマにおける抗腫瘍免疫を誘発し、t6A tRNA修飾を抗腫瘍免疫の治療標的として示唆する。
科学分野:
- 腫瘍学
- 分子生物学
- 免疫学
背景:
- 腫瘍誘発性免疫回避機構は、特にメラノーマにおいて、抗がん免疫応答を妨げる。
- がんの表現型および免疫応答の調節におけるmRNA翻訳の役割は認識されているが、根本的なメカニズムは不明である。
研究 の 目的:
- O-シアログリコプロテインエンドペプチダーゼ(OSGEP)ががんの免疫回避維持に果たす役割を解明すること。
- OSGEPを介したtRNA修飾(t6A)がメラノーマの表現型および抗腫瘍免疫に及ぼす影響を調査すること。
主な方法:
- メラノーマ細胞におけるOSGEPの機能を調査した。
- mRNA翻訳、タンパク質恒常性、およびストレス顆粒形成に対するt6A欠損の影響を分析した。
- RIG-I局在および免疫細胞動員に対するOSGEP喪失の影響を評価した。
- OSGEP駆動遺伝子シグネチャとメラノーマ患者の臨床転帰との関連を調べた。
主要な成果:
- OSGEPは、メラノーマにおけるタンパク質恒常性および免疫回避に不可欠なN6-トレオニルカルバモイルアデノシン(t6A)修飾を触媒する。
- t6A欠損メラノーマ細胞は、ANNコドンの翻訳障害を示し、タンパク質凝集およびストレス顆粒形成につながる。
- OSGEPの喪失は、ストレス顆粒への再配置を介してRIG-I経路を活性化することによりメラノーマの退縮を促進し、T細胞の動員および抗腫瘍免疫を高める。
- OSGEP駆動遺伝子シグネチャは、メラノーマ患者におけるT細胞浸潤の増加および生存率の改善と関連している。
結論:
- OSGEPは、t6A tRNA修飾を介してメラノーマの免疫回避表現型の維持に重要な役割を果たしている。
- t6A tRNA修飾を標的とすることは、メラノーマにおける抗腫瘍免疫を高めるための潜在的な治療戦略を表す。
関連する概念動画
Experimental RNAi
8.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.0K
Regulation of the Unfolded Protein Response
3.1K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.1K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
RNA Interference
28.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.2K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
PI3K/mTOR/AKT Signaling Pathway
5.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.8K


